DEXCOM INC

NASDAQ: DXCM (DexCom, Inc.)

Kemas kini terakhir: 4 jam lalu

65.49

0.24 (0.37%)

  • 1H 0.37%
  • 5H 3.18%
  • 1B 19.42%
  • 6B -23.56%
  • Tahun Ke Tarikh -16.57%
  • 1T -16.48%
  • 5T -24.76%
Penutupan Terdahulu 65.25
Buka 65.38
Jumlah Dagangan 3,854,687
Purata Dagangan (3B) 6,419,949
Modal Pasaran 25,682,247,680
Harga / Pendapatan (P/E TTM) 36.38
Harga / Pendapatan (P/E Ke hadapan) 25.84
Harga / Jualan (P/S) 5.85
Harga / Buku (P/B) 9.28
Julat 52 Minggu
54.11 (-17%) — 93.25 (42%)
Tarikh Pendapatan 30 Oct 2025
Margin Keuntungan 12.90%
Margin Operasi (TTM) 12.91%
EPS Cair (TTM) 1.33
Pertumbuhan Hasil Suku Tahunan (YOY) 12.50%
Pertumbuhan Pendapatan Suku Tahunan (YOY) -28.00%
Jumlah Hutang/Ekuiti (D/E MRQ) 113.97%
Nisbah Semasa (MRQ) 1.50
Aliran Tunai Operasi (OCF TTM) 964.10 M
Aliran Tunai Bebas Leveraj (LFCF TTM) 509.04 M
Pulangan Atas Aset (ROA TTM) 5.97%
Pulangan Atas Ekuiti (ROE TTM) 23.72%

Arah Aliran Pasaran

Jangka Pendek Jangka Sederhana
Industri Medical Devices (US) Bercampur Bercampur
Medical Devices (Global) Bercampur Bercampur
Stok DexCom, Inc. Menurun Menurun

AISkor Stockmoo

1.4
Konsensus Penganalisis 2.0
Aktiviti Orang Dalam NA
Volatiliti Harga 1.5
Purata Bergerak Teknikal 0.0
Osilator Teknikal 2.0
Purata 1.38

Saham Serupa

Stok Modal Pasaran DY P/E (TTM) P/B
DXCM 26 B - 36.38 9.28
PODD 22 B - 97.43 15.47
SSII 1 B - - 30.33
IRTC 6 B - - 48.07
TMDX 4 B - 51.55 14.05
ESTA 2 B - - 125.60

Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.
Sektor Healthcare
Industri Medical Devices
Gaya Pelaburan Mid Growth
% Dimiliki oleh Orang Dalam 0.42%
% Dimiliki oleh Institusi 97.10%

Pemilikan

Nama Tarikh Syer Dipegang
Baillie Gifford & Co 30 Sep 2025 15,882,168
Jennison Associates Llc 30 Sep 2025 10,090,374
Nuveen Asset Management, Llc 31 Dec 2024 8,138,522
Ubs Am, A Distinct Business Unit Of Ubs Asset Management Ame 30 Sep 2025 7,482,531
Nuveen, Llc 30 Sep 2025 6,343,476
Amundi 30 Sep 2025 5,019,475
Sands Capital Management, Llc 30 Sep 2025 4,934,189
Julat 52 Minggu
54.11 (-17%) — 93.25 (42%)
Julat Harga Sasaran
68.00 (3%) — 99.00 (51%)
Tinggi 99.00 (Canaccord Genuity, 51.17%) Beli
Median 85.00 (29.79%)
Rendah 68.00 (Evercore ISI Group, 3.83%) Pegang
Purata 83.82 (27.99%)
Jumlah 14 Beli, 3 Pegang
Harga Purata @ Panggilan 60.65
Syarikat Tarikh Harga Sasaran Panggilan Harga @ Panggilan
Morgan Stanley 02 Dec 2025 75.00 (14.52%) Beli 64.45
10 Nov 2025 63.00 (-3.80%) Pegang 54.84
Evercore ISI Group 25 Nov 2025 68.00 (3.83%) Pegang 61.69
Argus Research 07 Nov 2025 90.00 (37.43%) Beli 55.00
Barclays 03 Nov 2025 80.00 (22.16%) Pegang 60.43
Truist Securities 03 Nov 2025 82.00 (25.21%) Beli 60.43
15 Oct 2025 94.00 (43.53%) Beli 65.41
UBS 03 Nov 2025 95.00 (45.06%) Beli 60.43
BTIG 31 Oct 2025 85.00 (29.79%) Beli 58.22
Canaccord Genuity 31 Oct 2025 99.00 (51.17%) Beli 58.22
29 Sep 2025 106.00 (61.86%) Beli 66.46
Citigroup 31 Oct 2025 75.00 (14.52%) Beli 58.22
07 Oct 2025 85.00 (29.79%) Beli 66.03
JP Morgan 31 Oct 2025 75.00 (14.52%) Pegang 58.22
Piper Sandler 31 Oct 2025 75.00 (14.52%) Beli 58.22
RBC Capital 31 Oct 2025 85.00 (29.79%) Beli 58.22
TD Cowen 31 Oct 2025 84.00 (28.26%) Beli 58.22
Wells Fargo 31 Oct 2025 93.00 (42.01%) Beli 58.22
Stifel 21 Oct 2025 85.00 (29.79%) Beli 69.75
Goldman Sachs 01 Oct 2025 89.00 (35.90%) Beli 66.08
Baird 26 Sep 2025 90.00 (37.43%) Beli 67.10
Papar semua

Tiada data dalam julat masa ini.

  • 3M
Tarikh Jenis Butiran
05 Dec 2025 Pengumuman Shareholders SueWallSt in New Class Action Against DexCom, Inc. - Act Now
05 Dec 2025 Pengumuman SueWallSt Podcast Series Launches With Focus on DexCom, Inc. (DXCM) Fraud Allegations
04 Dec 2025 Pengumuman Shareholders SueWallSt in New Class Action Against DexCom, Inc. - Act Now
04 Dec 2025 Pengumuman Listening to Healthcare Professionals: Dexcom Launches New Education Offering, Dexcom Academy
04 Dec 2025 Pengumuman DexCom, Inc. (DXCM) Investors: December 26, 2025 Filing Deadline in Securities Class Action - Contact Lieff Cabraser
03 Dec 2025 Pengumuman Investors SueWallSt as DexCom, Inc. Faces Securities Fraud Allegations
02 Dec 2025 Pengumuman DexCom, Inc. (DXCM) Investors: December 26, 2025 Filing Deadline in Securities Class Action - Contact Lieff Cabraser
02 Dec 2025 Pengumuman Tune Into the SueWallSt Podcast: DexCom, Inc. (DXCM) Lawsuit Explained
01 Dec 2025 Pengumuman DexCom, Inc. (DXCM) Investors: December 26, 2025 Filing Deadline in Securities Class Action - Contact Lieff Cabraser
01 Dec 2025 Pengumuman Tune Into the SueWallSt Podcast: DexCom, Inc. (DXCM) Lawsuit Explained
25 Nov 2025 Pengumuman GlucoGuard a Division of American Diversified Holdings (ADHC) Successfully Submits Level 2 App Integration Through Dexcom's Developer Partner Program
25 Nov 2025 Pengumuman DexCom, Inc. (DXCM) Investors: December 26, 2025 Filing Deadline in Securities Class Action - Contact Lieff Cabraser
24 Nov 2025 Pengumuman DexCom, Inc. (DXCM) Investors: December 26, 2025 Filing Deadline in Securities Class Action - Contact Lieff Cabraser
20 Nov 2025 Pengumuman Dexcom G7 15 Day Continuous Glucose Monitoring System to Launch on Dec. 1 in the United States
20 Nov 2025 Pengumuman DexCom, Inc. (DXCM) Investors: December 26, 2025 Filing Deadline in Securities Class Action - Contact Lieff Cabraser
19 Nov 2025 Pengumuman Dexcom Smart Basal Receives FDA Clearance Becoming the First and Only CGM-integrated Basal Insulin Dosing Optimizer for Type 2 Diabetes
18 Nov 2025 Pengumuman Investors SueWallSt as DexCom, Inc. Faces Securities Fraud Allegations
18 Nov 2025 Pengumuman DexCom, Inc. (DXCM) Investors: December 26, 2025 Filing Deadline in Securities Class Action - Contact Lieff Cabraser
17 Nov 2025 Pengumuman Investors SueWallSt as DexCom, Inc. Faces Securities Fraud Allegations
14 Nov 2025 Pengumuman Dexcom Reveals Global Diabetes Advocates: New Voices for Diabetes Awareness This World Diabetes Day
06 Nov 2025 Pengumuman Québec Expands Access to Dexcom CGM under the Régie de l'assurance maladie du Québec (RAMQ)
06 Nov 2025 Pengumuman Shareholders SueWallSt in New Class Action Against DexCom, Inc. - Act Now
30 Oct 2025 Pengumuman Dexcom Reports Third Quarter 2025 Financial Results and Updates Full Year 2025 Guidance
27 Oct 2025 Pengumuman Dexcom Appoints Euan Ashley to Board of Directors
02 Oct 2025 Pengumuman Dexcom Schedules Third Quarter 2025 Earnings Release and Conference Call for October 30, 2025 at 4:30 p.m. Eastern Time.
15 Sep 2025 Pengumuman Dexcom Spotlights Upcoming Feature Launches, Improved Health Outcomes and Cost-Effectiveness With Dexcom Glucose Biosensing at EASD 2025
10 Sep 2025 Pengumuman Dexcom Launches Its First Open Call to Uncover the Next Diabetes Advocates Ahead of World Diabetes Day
Papar semua

Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.

Portfolio

AI Templat

Peringatan harga anda

Profil Risiko

| | | | |
Konservatif
Sederhana Konservatif
Sederhana
Sederhana Agresif
Agresif
Margin Keselamatan (EP)
Keuntungan Separa (TP1)
Keuntungan Sasaran (TP2)
Kerugian Maksimum (SL)

Penafian: Perkara di atas adalah untuk tujuan ilustrasi sahaja dan BUKAN nasihat pelaburan. Dapatkan nasihat daripada penasihat kewangan yang berkelayakan.

Harga Masuk (EP)

Ambil Untung 1 (TP1)

Ambil Untung 2 (TP2)

Henti Rugi (SL)

Julat 52 Minggu
 
52WL
 
52WH
SL
EP
TP1
TP2

Semua harga peringatan berada dalam julat harga 52 minggu

Keuntungan Nyata -
Keuntungan Tidak Nyata -
Dividen Diterima 2025 -
Jumlah Untung -
Pulangan Purata -
Kuantiti (Beli) -
Purata Harga (Beli) -
Kuantiti (Jual) -
Purata Harga (Jual) -
Tiada saham yang memenuhi kriteria anda